Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

In this trial, 261 patients with chronic thromboembolic pulmonary hypertension were assigned to placebo or to the soluble guanylate cyclase stimulator riociguat. At 16 weeks, riociguat had significantly improved the 6-minute walk distance and pulmonary vascular resistance. Chronic thromboembolic pul...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 369; no. 4; pp. 319 - 329
Main Authors Ghofrani, Hossein-Ardeschir, D'Armini, Andrea M, Grimminger, Friedrich, Hoeper, Marius M, Jansa, Pavel, Kim, Nick H, Mayer, Eckhard, Simonneau, Gerald, Wilkins, Martin R, Fritsch, Arno, Neuser, Dieter, Weimann, Gerrit, Wang, Chen
Format Journal Article
LanguageEnglish
Published Waltham, MA Massachusetts Medical Society 25.07.2013
Subjects
Online AccessGet full text

Cover

Loading…